The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
Ocuphire Presenting New Data And Updates On APX3330 And Nyxol Clinical Programs At Virtual Investor R&D Day
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia
First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients enrolled
New masked
Ocuphire Provides Corporate Update: Announces Enrollment Completion Of Phase 3 Nyxol Trial, Enrollment Initiation Of Nyxol Pediatric Trial And Investor R&D Day In January
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
Initiated Enrollment of Nyxol MIRA-4 Pediatric Study in RM per Agreed Initial Pediatric Study Plan with FDA
Nyxol MIRA-3 Phase 3 Results, MIRA-4 Pediatric
Mid-Afternoon Market Update: Dow Falls 75 Points; Biofrontera Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded down 0.21% to 35,738.42 while the NASDAQ rose 0.06% to 15,784.86. The S&P also rose, gaining 0.01% to 4,690.76.
HC Wainwright & Co. Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $26
HC Wainwright & Co. analyst Andrew Fein initiates coverage on Ocuphire Pharma (NASDAQ:OCUP) with a Buy rating and announces Price Target of $26.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 6.47% to $2.63 during Thursday's after-market session. The company's market cap stands at $41.4 million.
Ocuphire Pharma Q3 EPS $(0.25) Up From $(0.33) YoY
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.25) per share. This is a 24.24 percent increase over losses of $(0.33) per share from the same period last year.